Phase 1 Hodgkin's Lymphoma Clinical Trials
32 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 32 trials
Recruiting
Phase 1
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Non-Hodgkin LymphomaHodgkin's Lymphoma
Baylor College of Medicine60 enrolled2 locationsNCT02917083
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
Non-Hodgkin's Lymphoma
Chinese PLA General Hospital9 enrolled1 locationNCT07620314
Recruiting
Phase 1Phase 2
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
Phase 1
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Non Hodgkin's Lymphoma Refractory/Relapsed
ImmunityBio, Inc.20 enrolled2 locationsNCT05618925
Recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Non-Hodgkin's Lymphoma+1 more
City of Hope Medical Center15 enrolled1 locationNCT05801913
Recruiting
Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
LymphomaNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Baylor College of Medicine136 enrolled3 locationsNCT01555892
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Phase 1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
AbbVie165 enrolled14 locationsNCT06667687
Recruiting
Phase 1
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Baylor College of Medicine52 enrolled2 locationsNCT04664179
Recruiting
Phase 1
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
PeproMene Bio, Inc.36 enrolled6 locationsNCT05370430
Recruiting
Phase 1
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Multiple MyelomaB Acute Lymphoblastic LeukemiaB-cell Non-Hodgkin's Lymphoma
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT07239323
Recruiting
Phase 1Phase 2
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Non-Hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06066203
Recruiting
Phase 1Phase 2
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled3 locationsNCT05623982
Recruiting
Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Hodgkin LymphomaNon-Hodgkin LymphomaHodgkin Lymphoma, Adult+4 more
Marker Therapeutics, Inc.79 enrolled7 locationsNCT05798897
Recruiting
Phase 1Phase 2
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
Ottawa Hospital Research Institute60 enrolled3 locationsNCT03765177
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1Phase 2
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Non-Hodgkin's Lymphoma
Chinese PLA General Hospital30 enrolled2 locationsNCT05554939
Recruiting
Phase 1Phase 2
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Non-Hodgkin's Lymphoma
Chinese PLA General Hospital30 enrolled3 locationsNCT06014073